US2010143388A1PendingUtilityA1

Antibody Composition-Producing Cell

74
Assignee: KYOWA HAKKO KIRIN CO LTDPriority: Oct 6, 2000Filed: Nov 30, 2009Published: Jun 10, 2010
Est. expiryOct 6, 2020(expired)· nominal 20-yr term from priority
A61P 37/02A61P 37/00A61P 37/08A61P 35/00A61P 31/12A61P 29/00A61P 31/04C07K 16/1145C07K 16/44C12N 15/8257C07K 16/32C12Y 204/01068C07K 16/2866C12N 9/90C07K 2317/41C07K 2317/732C12N 15/8245C12N 15/8258C07K 16/2863C07K 2319/30C12N 9/1051C07K 16/2812C12P 21/005C07K 16/2896C07K 2317/565C07K 2317/24C07K 16/2887C07K 16/241C12N 9/0006C07K 16/3084C07K 16/18C12P 21/00
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

Claims

exact text as granted — not AI-modified
1 . An antibody composition comprising antibody molecules, wherein 50% or more of the molecules comprise a Fc region comprising complex N-glycoside-linked sugar chains bound to the Fc region,
 wherein said sugar chains comprise a reduced terminal which contains an N-acetylglucosamine;   wherein said sugar chains do not contain fucose bound to the 6-position of the N-acetylglucosamine in the reducing terminal of the sugar chains; and   wherein said antibody molecules bind to an antigen expressed by cancer cells, said antigen is CD20.   
     
     
         2 . The antibody composition according to  claim 1 , wherein the antibody molecules are molecules selected from the group consisting of (a), (b) and (c):
 (a) human antibodies;   (b) humanized antibodies;   (c) antibody fragments.   
     
     
         3 . The antibody composition according to  claim 1 , wherein the antibody molecules belong to an IgG class. 
     
     
         4 . A composition comprising the antibody composition according to  claim 1  and a carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.